Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must understand and voluntarily sign an informed consent form.~* Must be ≥ 18 years of age at the time of signing the informed consent form.~* Must be able to adhere to the study visit schedule and other protocol requirements.~* Biopsy-proven T-cell Non-Hodgkin's Lymphoma, either:~  * Peripheral T-cell Lymphoma (PTCL) whatever the subtype, or~ * Cutaneous T-cell Lymphoma (CTCL), but only the subtype mycosis fungoides.~* Relapsed or refractory to previous therapy for T-cell Non-Hodgkin's Lymphoma.~* Must have received at least one prior combination chemotherapy regimen. There is no limit on the number of prior therapies.~Exclusion Criteria:~* Cutaneous T-cell Lymphoma of subtype Sézary Syndrome.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide (Type: EXPERIMENTAL): Open-label, oral lenalidomide monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).